OXiGENE, Inc. (NASDAQ: OXGN, XSSE: OXGN), a clinical-stage, biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases, today reported positive results from preclinical studies with topical formulations of ZYBRESTAT for ophthalmological indications. The studies, performed in industry-standard rabbit models, indicate that two formulations of ZYBRESTAT, when applied topically to the surface of the eye, are absorbed and result in concentrations of drug in target tissues in the back of the eye (i.e., the retina and horoids) that the Company believes will be sufficient for therapeutic activity in age-related macular degeneration (ARMD) and potentially other eye diseases in which abnormal neovascularization plays a role. These results confirm preliminary results seen in earlier preclinical studies.
